TAT-cyclo-CLLFVY TFA is a cyclic peptide inhibitor specifically targeting HIF-1 heterodimerization to mitigate hypoxia signaling within cancer cells. It effectively disrupts the protein-protein interaction between HIF-1α and HIF-1β, demonstrating an inhibitory concentration (IC 50) of 1.3 μM [1].